ArticleChemistry & biodiversity2025
Bee-Derived Antioxidants as a Protective Strategy Against Doxorubicin-Induced Ovarian Damage.
Article in Chemistry & biodiversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Honey as a Natural Flavorful Product: A Comprehensive Review of Its Potential Biological Activities and Recent Studies.Food science & nutrition · 2026Review
- The Impact of Oxidative Stress Imbalance on Ovarian Function and Its Mechanisms.International journal of general medicine · 2026Review
- Bee-Derived Antioxidants as a Protective Strategy Against Doxorubicin-Induced Ovarian Damage.Chemistry & biodiversity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antineoplastic agents can induce tissue damage through oxidative stress mechanisms. Doxorubicin, a widely used chemotherapeutic agent, has been shown to cause permanent damage to reproductive tissues. Antioxidant-rich dietary interventions are considered a promising approach to mitigate oxidative stress-related damage. This study aimed to evaluate the therapeutic potential of an antioxidant-rich bee product mixture (ARPM) in ameliorating doxorubicin-induced ovarian injury. The ARPM, composed of honey, pollen, propolis, and royal jelly, was administered via gavage to female Sprague-Dawley rats (180-200 g) following chronic ovarian damage induced by doxorubicin (6 mg/kg, ip). Oxidative stress markers, including superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione (GSH), as well as endoplasmic reticulum (ER) stress-related markers such as 78-kDa glucose-regulated protein (GRP78), inositol-requiring enzyme 1 (IRE1), C/EBP homologous protein (CHOP), tumor necrosis factor-alpha (TNF-α), and caspase-3, were simultaneously evaluated. In addition, estradiol (E2) and progesterone levels were measured, and histopathological evaluations were conducted. The mixture, rich in bioactive compounds including chrysin, pinocembrin, caffeic acid, ferulic acid, and coumaric acid, was found to significantly improve ovarian function by reducing ER stress compared to the control group. These findings suggest that ARPM may offer protective effects against doxorubicin-induced ovarian damage through its antioxidative and anti-ER stress properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.